The US Food and Drug Administration approved the intravenous formulation of a drug as an alternative therapy option for patients experiencing chemotherapy-induced nausea and vomiting.

News

The US Food and Drug Administration approved the intravenous formulation of a drug as an alternative therapy option for patients experiencing chemotherapy-induced nausea and vomiting.
The US Food and Drug Administration approved a drug for the second-line treatment of thrombocytopenia.
Taxane acute pain syndrome reduces quality of life and increases the need for pharmaceutical interventions among patients with cancer receiving taxane-based chemotherapy.
A secondary analysis determined the most important factors in early palliative care that are associated with patient-reported outcomes and the delivery of end-of-life care.
Subscribe to Supportive Care